Raymond James & Associates Esperion Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 50,657 shares of ESPR stock, worth $122,083. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,657

Previous 56,877 10.94%

Holding current value

$122,083

Previous $126,000 34.13%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$1.61 - $2.73 $10,014 - $16,980	-6,220 Reduced 10.94%	50,657 $83,000
Q1 2024 Apr 22, 2024	BUY	$2.02 - $3.02 $35,404 - $52,931	17,527 Added 44.54%	56,877 $152,000
Q4 2023 Jan 16, 2024	BUY	$0.73 - $3.08 $12,874 - $54,318	17,636 Added 81.22%	39,350 $117,000
Q3 2023 Oct 24, 2023	BUY	$0.96 - $1.79 $4,394 - $8,194	4,578 Added 26.72%	21,714 $21,000
Q2 2023 Jul 25, 2023	BUY	$1.2 - $1.76 $3,357 - $4,924	2,798 Added 19.51%	17,136 $23,000
Q1 2023 Apr 14, 2023	SELL	$1.46 - $7.3 $34,441 - $172,207	-23,590 Reduced 62.2%	14,338 $22,000
Q4 2022 Feb 08, 2023	BUY	$5.09 - $8.5 $193,053 - $322,388	37,928 New	37,928 $236,000
Q2 2022 Aug 12, 2022	BUY	$4.77 - $6.67 $51,706 - $72,302	10,840 New	10,840 $69,000
Q2 2021 Aug 11, 2021	SELL	$19.4 - $28.71 $440,787 - $652,319	-22,721 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$25.12 - $36.89 $280,364 - $411,729	11,161 Added 96.55%	22,721 $637,000
Q4 2020 Feb 12, 2021	BUY	$24.2 - $35.76 $64,541 - $95,371	2,667 Added 29.99%	11,560 $301,000
Q3 2020 Nov 04, 2020	BUY	$31.18 - $52.71 $122,475 - $207,044	3,928 Added 79.11%	8,893 $331,000
Q2 2020 Jul 28, 2020	BUY	$30.04 - $51.31 $149,148 - $254,754	4,965 New	4,965 $255,000
Q1 2020 Apr 21, 2020	SELL	$27.44 - $73.84 $109,074 - $293,514	-3,975 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$35.4 - $59.82 $140,715 - $237,784	3,975 New	3,975 $237,000
Q3 2019 Nov 07, 2019	SELL	$34.47 - $47.53 $174,418 - $240,501	-5,060 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$40.1 - $52.33 $202,906 - $264,789	5,060 New	5,060 $235,000
Q4 2018 Feb 11, 2019	SELL	$36.99 - $59.11 $247,796 - $395,977	-6,699 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$40.74 - $51.41 $272,917 - $344,395	6,699 New	6,699 $297,000
Q3 2017 Nov 13, 2017	SELL	$43.8 - $52.77 $227,759 - $274,404	-5,200 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	5,200	5,200 $241,000

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Esperion Therapeutics, Inc. Transaction History